Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Sorrento has been granted an exclusive license to develop and commercialize the ACE-MAB product candidate in the North American and European markets.
Lead Product(s): ACE-MAB
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Sorrento Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement March 24, 2020